Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Low Titer O Whole Blood
- Development stage
- Preclinical
- Lead developer
- Military blood services
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Low Titer O Whole Blood (LTO-WB) is a specialized labile blood product designed for the emergency resuscitation of patients experiencing severe hemorrhage. Unlike conventional component therapy, which separates blood into red blood cells, plasma, and platelets, LTO-WB provides all these components in a single unit, maintaining a physiological ratio of cells and clotting factors. The 'Low Titer' designation refers to the selection of group O donors with low levels of anti-A and anti-B antibodies, which minimizes the risk of hemolytic transfusion reactions and allows for universal administration in emergency settings without prior cross-matching. In France, the Centre de Transfusion Sanguine des Armées (CTSA) produces a leukocyte-free version of LTO-WB, which is currently being evaluated by the Etablissement Français du Sang (EFS) in the PEDESTAL EFS study to characterize its biological properties and storage lesions compared to standard blood components.
- Other names
- Group O leukocyte-free whole bloodLow Titer O Whole Blood-Etablissement Français du Sang-hemorrhage
Beyond the preview
Go deeper on Low Titer O Whole Blood.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Low Titer O Whole Blood.